| 產(chǎn)品編號(hào) | bs-0080R |
| 英文名稱(chēng) | Rabbit Anti-CD20 antibody |
| 中文名稱(chēng) | CD20抗體 |
| 別 名 | CD20_HUMAN; B-lymphocyte antigen CD20; B-lymphocyte surface antigen B1; Bp35; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 1; MS4A1; MS4A2; B1; CVID5; LEU-16; S7. |
 |
Specific References (3) | bs-0080R has been referenced in 3 publications.
[IF=17.694] Lei, Xinyuan. et al. Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression. NAT COMMUN. 2022 Jul;13(1):1-16 IHC ; Mouse.
[IF=3.514] Liu Y et al. Activation of the IL-6/JAK2/STAT3 pathway induces plasma cell mastitis in mice.Cytokine. 2018 Oct;110:150-158. IHC-P ; Mouse.
[IF=1.665] Ane M. Andres. et al. Graft infusion of adipose‐derived mesenchymal stromal cells to prevent rejection in experimental intestinal transplantation: A feasibility study. 2021 Feb 05 IHC ; Rat.
|
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 干細(xì)胞 細(xì)胞表面分子 細(xì)胞類(lèi)型標(biāo)志物 淋巴細(xì)胞 b-淋巴細(xì)胞 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | Mouse (predicted: Human,Rat) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,Flow-Cyt=1μg /Test,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 33 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CD20: 133-182/297 <Cytoplasmic> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
CD20 is a non glycosylated protein with a molecular weight of 35 or 37 kDa depending on the degree of phosphorylation. Although not a member of the tetraspanin superfamily of cell surface receptors, it crosses the cell membrane four times. The CD20 antigen is present on human pre B lymphocytes and on B lymphocytes at all stages of maturation, except on plasma cells. Low level expression of the CD20 antigen has been detected on normal T lymphocytes. The CD20 molecule is involved in regulation of B cell differentiation, presumably via its reported function as a Ca++ channel subunit. Function: This protein may be involved in the regulation of B-cell activation and proliferation Subcellular Location: Membrane; Multi-pass membrane protein. Tissue Specificity: Expressed on B-cells. Post-translational modifications: Phosphorylated. Might be functionally regulated by protein kinase(s). DISEASE: Defects in MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5) [MIM:613495]; also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low. Similarity: Belongs to the MS4A family. SWISS: P11836 Gene ID: 931 Database links: Entrez Gene: 931 Human Omim: 112210 Human SwissProt: P11836 Human Unigene: 712553 Human [PHARMACEUTICAL] Monoclonal antibodies (mAb) against CD20 are used to treat B-cell non-Hodgkin lymphoma (NHL). These antibodies include Rituximab (Mabthera), Britumomab (Zevalin) and Tositumomab (Bexxar). CD20 engaged by mAb can generate transmembrane signals capable of directly controlling cell growth and triggering cell death in certain tumors. Alternatively, mAb can mediate complement-dependent cytotoxicity. B淋巴細(xì)胞標(biāo)志物 CD20是B細(xì)胞特異性抗原，其表達(dá)呈細(xì)胞類(lèi)型一種質(zhì)膜蛋白質(zhì)，參與信號(hào)傳導(dǎo)作用，此抗體識(shí)別大多數(shù)B細(xì)胞上的一種抗原。多用于標(biāo)記B淋巴細(xì)胞及B細(xì)胞淋巴瘤。 CD20一般不與T細(xì)胞交叉反應(yīng)，對(duì)B細(xì)胞淋巴瘤和急慢性淋巴細(xì)胞白血病等有較好的細(xì)胞特異性，因此在惡性淋巴瘤，尤其是T或B細(xì)胞淋巴瘤的分類(lèi)上，CD20是最常用的B細(xì)胞標(biāo)志。 |
| 產(chǎn)品圖片 |
Sample:
Lane 1: Lymph node (Mouse) Lysate at 40 ug
Lane 2: Bone (Mouse) Lysate at 40 ug
Primary: Anti-CD20 (bs-0080R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 43 kD
Observed band size: 43 kD
Blank control: U937 (blue). Primary Antibody:Rabbit Anti- CD20 antibody(bs-0080R), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG(orange) ,used under the same conditions ); Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA.
Protocol
The cells were fixed with 2% paraformaldehyde (10 min) . Primary antibody (bs-0080R, 1μg /1x10^6 cells) were incubated for 30 min on the ice, followed by 1 X PBS containing 0.5% BSA + 1 0% goat serum (15 min) to block non-specific protein-protein interactions. Then the Goat Anti-rabbit IgG/PE antibody was added into the blocking buffer mentioned above to react with the primary antibody at 1/200 dilution for 30 min on ice. Acquisition of 20,000 events was performed.
|
